Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Licenses Technology to Nanosphere for $1.9M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Acceler8 and Nanosphere have reached a non-exclusive licensing agreement for Acceler8's surface coating technology.

The deal, disclosed in a document filed by Nanosphere with the US Securities and Exchange Commission, covers "a coating to be applied to a single discrete physical substrate component article." The coating is "a polymer formulation comprising of an active component comprising polyethylene glycol polymer; a matrix-forming component; and a cross-linking component."

Under the terms of the deal, Nanosphere will pay Accelr8 a license and technology transfer fee of almost $1.9 million payable in four installments. The first installment of $165,000 was due upon execution of the deal. The remaining installments — $350,000, $600,000, and $750,000 — are due on July 9, 2011, 2012, and 2013, respectively.

The deal was reached on July 9, said Nanosphere.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.